top of page

14 minutes ago1 min read
Key Takeaways from the 21st Annual WORLDSymposium on Lysosomal Disease Research (11 February, 2025)
The field of lysosomal disorders is making great strides, with breakthroughs in basic science paving the way for potential new...
1 view0 comments

Feb 31 min read
Meet Release Tx at the WORLDSymposium™ on Lysosomal Disease Research (3–7 February 2025)
We are thrilled to announce that Release Therapeutics is attending the 21st annual WORLDSymposium ™ on Lysosomal Disease Research held...
8 views0 comments

Jan 303 min read
Release Therapeutics Announces New CEO to Advance Groundbreaking Treatment for Brain Disorders (30 January 2025)
Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...
136 views0 comments

Dec 23, 20241 min read
Release Tx Announces Scientific Advisory Board (SAB; 23 December 2024)
We are thrilled to introduce Release Tx's Scientific Advisory Board (SAB), which brings together leading experts in leukodystrophies,...
40 views0 comments

Nov 21, 20241 min read
Release Tx to attend 134th SICTIC Investor Day at IMD Lausanne (28 November 2024)
All of us at Release Tx are excited to be participating in the the 134th SICTIC Investor Day at IMD, Lausanne on 28 November 2024, where...
31 views0 comments


Nov 19, 20241 min read
Release Tx to attend Lenz & Staehelin Founders’ Evening (20 November 2024)
We’re pleased to announce that Release Therapeutics will be attending Founders’ Evening, organised by Lenz & Staehelin on 20 November at...
17 views0 comments

Nov 7, 20241 min read
Release Tx to attend Cell Press Tumor Immunology and Immunotherapy Symposium (11 – 12 November 2024)
We are pleased to announce that Release Tx will participate in the upcoming Cell Press LabLinks Tumor Immunology and Immunotherapy...
11 views0 comments

Oct 17, 20241 min read
Meet Release Tx at the ESGCT Congress in Rome (22–25 October 2024)
Release Therapeutics is pleased to announce our participation in the European Society of Gene and Cell Therapy (ESGCT) Congress that will...
13 views0 comments

Sep 25, 20241 min read
Meet Release Tx at FutureHealth Lausanne 2024 (1 October 2024)
Release Therapeutics is thrilled to announce our participation in FutureHealth Lausanne 2024, which kicks off at the SwissTech Convention...
26 views0 comments

Aug 6, 20242 min read
Release Therapeutics Secures CHF 3.3 Million in Seed Funding
The funding follows the Company’s first preclinical results in metachromatic leukodystrophy and will be invested in studies in non-human...
160 views0 comments


Jul 19, 20243 min read
Release Tx Announces Research Collaboration with Paris Brain Institute to Treat Metachromatic Leukodystrophy (MLD) and First Preclinical Results
We are thrilled to announce our strategic collaboration with Paris Brain Institute to explore the potential of our cutting-edge cell...
156 views0 comments

Jun 27, 20242 min read
Press Release: Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy
107 views0 comments

Jun 18, 20247 min read
Release Therapeutics publishes cutting-edge research in Cell Press
Release Therapeutics publishes cutting-edge research in Cell Press
155 views0 comments

Jun 15, 20246 min read
Treating Genetic Disorders of the CNS without Gene Therapy (or what we’ve been up to here at Release Therapeutics)
Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.
175 views0 comments

Jun 14, 20241 min read
Meet us online at RESI Europe (18-19 June 2024)
Release Therapeutics is excited to announce our participation in the virtual partnering segment of RESI Europe, Barcelona from June...
9 views0 comments

Jan 13, 20241 min read
Meet us at the WORLDSymposium
Release Tx will join the 20th annual WORLDSymposium in San Diego. https://worldsymposia.org/
20 views0 comments

Oct 20, 20231 min read
Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
AACR American Association for Cancer Research Orlando Florida Poster Grogg et al. 2023. iScience. Engineering a versatile and retrievable...
20 views0 comments


Sep 15, 20231 min read
MaxiVAX transitions into Release Tx
We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into...
66 views0 comments


May 31, 20221 min read
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
Molecular Therapy – Methods & Clinical Development Immortalized human myoblast cell lines for the delivery of therapeutic proteins using...
14 views0 comments

Jan 11, 20221 min read
Best Poster Awards 2022: Personalized immunotherapy with encapsulated cell technology
Best Poster Awards 2022 – ESMO conference – Our ECT technology as adjuvant to an au tologous cancer vaccine.
9 views0 comments
bottom of page